Research Triangle Park, N.C., Oct. 21, 2003 GlaxoSmithKline (GSK) today announced that the Food and Drug Administration has granted marketing clearance for Lexiva (fosamprenavir calcium) (Lex-ee'-va, formerly GW433908, or 908), a new protease inhibitor (PI) for the treatment of HIV infection in adults in combination with other antiretroviral medications. The following points should be considered when initiating therapy with Lexiva/ritonavir (Lexiva/r) in PI-experienced patients: the PI-experienced patient study was not large enough to reach a definitive conclusion that Lexiva/r and lopinavir/ritonavir are clinically equivalent. Once-daily administration of Lexiva plus ritonavir is not recommended for PI-experienced patients. Lexiva was co-discovered by GSK and Vertex Pharmaceuticals (Nasdaq: VRTX).
Lexiva, a PI that can be taken once or twice daily without food or water restrictions, has been evaluated in clinical trials with both PI-experienced and antiretroviral therapy (ART)-nave HIV patients.
Lexiva may be dosed three different ways: 1) two 700mg tablets twice daily (BID), 2) two 700mg tablets once daily (QD) in combination with two 100mg capsules of ritonavir QD (Lexiva/r QD), or 3) one 700mg tablet BID in combination with one 100mg capsule of ritonavir BID (Lexiva/r BID). For PI-experienced patients, the recommended dose is one 700mg tablet BID in combination with one 100mg capsule of ritonavir BID.
"The drug's QD and BID dosing options with no food or water restrictions, and a low pill burden demonstrate GSK's ongoing commitment to providing flexible anti-HIV therapies for patients," said Doug Manion, M.D., vice president of clinical development and medical affairs at GSK.
More than 1,200 people both ART-nave and PI-experienced patients participated in three Phase III trials to test the safety and efficacy of Lexiva with and without ritonavir. In all three trials, study drugs were taken as part of combination therapy that inclPage: 1 2 3 4 5 Related medicine news :1
Contact: Elaine Salewske
Public Communications Inc.
. FDA approves Pfizers Lyrica for the treatment of the two most common forms of neuropathic pain2
. FDA approves Enablex for treatment of overactive bladder3
. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients4
. FDA approves Adderall XR (R) to treat ADHD in adults5
. FDA approves EPZICOM6
. FDA approves new labelling for Seroquel in bioplar mania7
. FDA approves Enbrel to treat psoriasis8
. FDA approves Climara Pro to treat menopause symptoms9
. FDA approves new approach to schizophrenia treatment10
. FDA approves Wellbutrin XL(TM)11
. FDA approves Baxters ADVATE for the treatment of hemophilia A